Standard Standard
Bendamustine prolongs progression-free survival in metastatic breast cancer (MBC): a phase III prospective, randomized, multicenter trial of bendamustine hydrochloride, methotrexate and 5-fluorouracil (BMF) versus cyclophosphamide, methotrexate and 5-fluorouracil (CMF) as first-line treatment of MBC. / Stuart, N.S.; von Minckwitz, G.; Chernozemsky, I. et al.
In:
Anti-Cancer Drugs, Vol. 16, No. 8, 01.09.2005, p. 871-877.
Research output: Contribution to journal › Article › peer-review
HarvardHarvard
Stuart, NS, von Minckwitz, G, Chernozemsky, I, Sirakova, L, Chilingirov, P, Souchon, R, Marschner, N, Kleeberg, U, Tsekov, C, Fritze, D, Thomssen, CF, Stuart, N, Vermorken, JB, Loibl, S, Merkle, KH & Kaufmann, M 2005, '
Bendamustine prolongs progression-free survival in metastatic breast cancer (MBC): a phase III prospective, randomized, multicenter trial of bendamustine hydrochloride, methotrexate and 5-fluorouracil (BMF) versus cyclophosphamide, methotrexate and 5-fluorouracil (CMF) as first-line treatment of MBC',
Anti-Cancer Drugs, vol. 16, no. 8, pp. 871-877.
APA
Stuart, N. S., von Minckwitz, G., Chernozemsky, I., Sirakova, L., Chilingirov, P., Souchon, R., Marschner, N., Kleeberg, U., Tsekov, C., Fritze, D., Thomssen, C. F., Stuart, N., Vermorken, J. B., Loibl, S., Merkle, K. H., & Kaufmann, M. (2005).
Bendamustine prolongs progression-free survival in metastatic breast cancer (MBC): a phase III prospective, randomized, multicenter trial of bendamustine hydrochloride, methotrexate and 5-fluorouracil (BMF) versus cyclophosphamide, methotrexate and 5-fluorouracil (CMF) as first-line treatment of MBC.
Anti-Cancer Drugs,
16(8), 871-877.
CBE
Stuart NS, von Minckwitz G, Chernozemsky I, Sirakova L, Chilingirov P, Souchon R, Marschner N, Kleeberg U, Tsekov C, Fritze D, et al. 2005.
Bendamustine prolongs progression-free survival in metastatic breast cancer (MBC): a phase III prospective, randomized, multicenter trial of bendamustine hydrochloride, methotrexate and 5-fluorouracil (BMF) versus cyclophosphamide, methotrexate and 5-fluorouracil (CMF) as first-line treatment of MBC.
Anti-Cancer Drugs. 16(8):871-877.
MLA
VancouverVancouver
Author
RIS
TY - JOUR
T1 - Bendamustine prolongs progression-free survival in metastatic breast cancer (MBC): a phase III prospective, randomized, multicenter trial of bendamustine hydrochloride, methotrexate and 5-fluorouracil (BMF) versus cyclophosphamide, methotrexate and 5-fluorouracil (CMF) as first-line treatment of MBC
AU - Stuart, N.S.
AU - von Minckwitz, G.
AU - Chernozemsky, I.
AU - Sirakova, L.
AU - Chilingirov, P.
AU - Souchon, R.
AU - Marschner, N.
AU - Kleeberg, U.
AU - Tsekov, C.
AU - Fritze, D.
AU - Thomssen, C.F.
AU - Stuart, N.
AU - Vermorken, J.B.
AU - Loibl, S.
AU - Merkle, K.H.
AU - Kaufmann, M.
PY - 2005/9/1
Y1 - 2005/9/1
M3 - Article
VL - 16
SP - 871
EP - 877
JO - Anti-Cancer Drugs
JF - Anti-Cancer Drugs
SN - 0959-4973
IS - 8
ER -
